Do you ever withhold adjuvant RT after BCS in older women with stage I triple positive/Luminal-Her2 subtype breast cancers?

If they receive herceptin-based chemotherapy, then local regional recurrence rates are similar to luminal A disease (excellent review on this subject by Wendy Woodward during her talk at ASTRO in 2016- accessible on virtual meeting). So by that logic, you could consider it in someone who has receive...